First-line afatinib in patients aged 75 or older with advanced non-squamous non-small cell lung cancer harboring EGFR mutations; non-randomized phase II trial
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 18 Dec 2017
At a glance
- Drugs Afatinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 14 Dec 2017 Status changed from recruiting to active, no longer recruiting.
- 12 Jun 2017 Status changed from not yet recruiting to recruiting.
- 05 Aug 2015 New trial record